OM-85
| Clinical data | |
|---|---|
| Trade names | Broncho-Vaxom |
| Other names | OM 85BV |
| Identifiers | |
| CAS Number | |
OM-85 or OM85 (trade name Broncho-Vaxom) is an immunostimulant. It is a combination of molecules extracted from the walls of bacteria that commonly cause respiratory infections.[1]
Uses[edit]
It has been sold, as Broncho-Vaxom, in Europe and some South American countries.[1] It is used for children with asthma or recurrent respiratory infections.[1]
Potential uses[edit]
It may help prevent Covid-19.[2]
It may prevent babies from developing asthma.[3][4]
Composition[edit]
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. (February 2022) |
It is a mix of lipopolysaccharides,[4] extracted from bacteria cell walls.
Clinical trials[edit]
It has been studied in numerous pediatric clinical trials.[2]
References[edit]
- ^ a b c Sly P (11 June 2020). "M85: could bacteria in a capsule protect us from coronavirus and other respiratory infections?".
- ^ a b Cao C, Wang J, Li Y, Li Y, Ma L, Abdelrahim ME, Zhu Y (May 2021). "Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis". International Journal of Clinical Practice. 75 (5): e13981. doi:10.1111/ijcp.13981. PMC 7883224. PMID 33405321.
- ^ Hart A (15 Feb 2022). "Aussie researchers make asthma breakthrough".
- ^ a b Troy NM, Strickland D, Serralha M, de Jong E, Jones AC, Read J, et al. (July 2022). "Protection against severe infant lower respiratory tract infections by immune training: Mechanistic studies". The Journal of Allergy and Clinical Immunology. 150 (1): 93–103. doi:10.1016/j.jaci.2022.01.001. hdl:10044/1/95014. PMID 35177255. S2CID 246844791.
 | This immunology article is a stub. You can help Wikipedia by expanding it. |